CONGRESS
OVERALL
Add like
Add dislike
Add to saved papers

Surveillance or adjuvant treatments in stage 1 testis germ-cell tumours.

All patients with stage 1 testicular germ-cell tumours (TGCT) can expect to be permanently cured with currently available management approaches. Orchidectomy alone cures 80% of pure seminomas and 70%-75% of nonseminomatous and combined seminoma plus nonseminomatous germ-cell tumours of the testis (NSGCTT). Currently there are well-validated criteria for estimating recurrence risk in NSGCTT. The presence of vascular invasion (VI+) in the testicular primary identifies a group with a recurrence risk approaching 50%. In VI-cases, the risk is ≤20%. Adjuvant chemotherapy with two cycles of bleomycin, etoposide, and cisplatin (BEP) is increasingly recommended in VI+ cases, and when offered is selected in place of surveillance by many VI- patients. In seminomatous germ-cell testicular tumours (SGCTT), there are no validated criteria for estimating recurrence risk. Concerns about second cancers complicating adjuvant radiotherapy are reducing its popularity and the absence of tumour markers, the need for frequent scans, long follow-up and evidence of poor compliance argue against surveillance. Single-dose carboplatin is well tolerated, cheap, reduces recurrence rates to <5% and also the risk of second primary TGCT. There remain concerns about long-term toxicity although evidence is accumulating to allay these. This article discusses the relevant issues affecting decision-making and choice in these intriguing, curable cancers.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app